Controlled comparison of trebenzomine with doxepin as an antidepressant-anxiolytic

Trebenzomine, a new psychotropic drug, was compared with doxepin in the treatment of anxiety and depression. The study was a three-week, double-blind trial involving 26 psychoneurotic inpatients. Multiple ratings by physician, nurse, and patient all concurred that the 2 drugs produced significant improvement in both depressive and anxious symptomatology. No significant differences were found between the 2 drugs either in terms of rate or degree of improvement or incidence of side effects. Further investigation of trebenzomine for anxious depression is warranted.